Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
September 11, 2025 09:00 ET | Source: Nacuity Pharmaceuticals, Inc. NPI-001 shows…
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for…
As Agentic AI Gains Traction, 86% of Enterprises Anticipate Heightened Risks, Yet Only 2% of Companies Meet Responsible AI Gold Standards
With 95% of enterprises facing incidents, Infosys research reveals wide gap between…
TrimIQ Weight Loss: Official launched in UK and Ireland With Green Tea Probiotic Complex
New York City, NY, Aug. 02, 2025 (GLOBE NEWSWIRE) -- TrimIQ UK,…
PMI Calls for Ongoing G2G Dialogues with Source and Transit Countries to Combat Illicit Tobacco Trade
- India faces an annual loss of approximately $1.65 billion, with 25%…
Pink Salt Trick Recipe to Weight Loss Trend 2025: An Analysis of Slumber Slim as a Science Informed Option
Albany, New York, July 26, 2025 (GLOBE NEWSWIRE) -- An internet-viral pink…
Justice4Heroes Campaign Demands Equality in Military Hearing Loss Compensation
Monday 21 July, 2025 PRESS RELEASE FOR IMMEDIATE RELEASE Justice4Heroes Campaign Demands…
Safest SARMs For Muscle Growth 2025: CrazyBulk IntroducesEffectiveSARMs For Bulking, Cutting and Strength in USA.
Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…